Table 1. Demographics and clinical patient characteristics.
| Demographics | Study cohort | Group 1 | Group 2 | Group 3 |
|---|---|---|---|---|
| n = 40 | n = 18 | n = 16 | n = 6 | |
| Characteristic | ||||
| Age, median | 58 (49–71) | 59 (52–64) | 54 (48–69) | 63 (46–83) |
| Sex, female n (%) | 18 (45) | 9 (50) | 7 (44) | 2 (33) |
| CCI, n | 2 (1–5) | 2 (1–4) | 2 (0–4) | 3 (1–7) |
| Hypertension n (%) | 16 (40) | 5 (28) | 7 (44) | 4 (67) |
| BMI, median | 28 (24–32) | 26 (22–30) | 28 (24–34) | 30 (26–34) |
| Nosocomial infection n (%) | 5 (13) | 4 (22) | 0 (0) | 1 (17) |
| Onset of symptoms to COVID-19 diagnosis (d), median | 8 (7–11) | 9 (8–20) | 8 (6–11) | 8 (5–8) |
| Days hospitalized, median | 7 (5–11) | 5 (3–10) | 7 (5–10) | 12 (9–33) |
| LMWH/NOAC/warfarin, n (%) | 32 (80) | 10 (56) | 16 (100) | 6 (100) |
| Antibiotics n (%) | 23 (58) | 5 (28) | 12 (75) | 6 (100) |
| Plasma n (%) | 2 (5) | 0 (0) | 2 (13) | 0 |
| Steroids n (%) | 8 (20) | 4 (22) | 2 (13) | 2 (33) |
| Treatment at ICU or IME (n) (%) | 3 (8) | 0 (0) | 0 (0) | 3 (50) |
| In hospital mortality n (%) | 2 (5) | 0 (0) | 0 (0) | 2 (33) |
| Clinical parameters | ||||
| CRP (mg/L), median | 92 (37–135) | 43 (12–114) | 117 (61–167) | 125 (72–294) |
| WBC (109 c/L), median | 8 (5–12) | 7 (4–10) | 8 (5–11) | 12 (8–17) |
| Neutrophils (109 c/L), median | 5 (4–9) | 4 (2–7) | 6 (4–9) | 8 (4–14) |
| Lymphocytes (109 c/L), median | 1 (0.7–1.4) | 1 (0.9–1.6) | 1 (0.6–1.3) | 0.8 (0.5–1) |
| Platelets (109 /L), median | 233 (185–299) | 239 (175–315) | 239 (196–314) | 186 (138–272) |
| PCT (μg/L), median** | 0.1 (0.07–0.3) | 0.07 (0.05–0.1) | 0.16 (0.1–0.3) | 0.4 (0.1–1.2) |
| IL-6 (ng/L), median | 57 (20–115) | 24 (19–111) | 58 (24–91) | 124 (53–236) |
Charlson Comorbidity score (CCI), body mass index (BMI), C-reactive protein (CRP), white blood cell (WBC), procalcitonin (PCT), low molecular weight heparin (LMWH), new oral anticoagulant (NOAC), intensive care unit (ICU), intermediate care (IME). For continuous variables interquartile range (IQR) is defined in the brackets. All clinical parameters are the median of every highest value for each patient, (except lymphocytes platelets where the lowest value for each patient was obtained.
* Defines statistical significance; CRP, (p < 0.05), between group 1 vs 2, adjusted p < 0.05.
** Defines statistical difference; PCT, (p < 0.001), between group 1 vs 2, adjusted p < 0.05 and group 1 vs group 3, adjusted p < 0.05.